SPP1 and triple-A syndrome: In the current study the effect of a promising new medical therapy will be assessed to determine whether a short course of fenofibrate will inhibit AAA-OPN expression and associated macrophage-based inflammation, whilst inducing other potential beneficial effects such as raising HDL.